/

ACAD

ACADIA Pharmaceuticals Inc.Open

18.75−0.66 −3.40%USD

NasdaqGS · as of Oct 13, 11:21 ET · 15m delay

Open

19.02

Prev close

19.41

Day range

18.7419.10

52-week range

18.7430.96

Volume

452.05K0.25×

Mkt cap

3.23B

P/E ttm

8.41

Fwd P/E

20.75

EPS ttm

2.23

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−39.44%

Price Chart

Yahoo Finance · delayed

ACADOct 13, 2026O 19.02H 19.10L 18.74C 18.75−0.66 (−3.40%)Vol 452.05K

SMA 5026.08
SMA 20024.12

1Y change −6.53% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ACAD ACADIA Pharmaceuticals Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.02%
1 month: −32.63%
3 months: −26.44%
6 months: −14.85%
Year to date: −29.80%
1 year: −6.53%

Valuation & ownership

Market cap: 3.23B
Enterprise value: 2.46B
P/E (ttm): 8.41
Forward P/E: 20.75
PEG ratio: 50.86
Price / book: 2.47
Price / sales (ttm): 2.84
EV / EBITDA: 25.02
EPS (ttm): 2.23
EPS (forward): 0.9035
Beta (5y monthly): 0.89
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 172.31M
Float: 128.35M
Short % of float: 7.59%
Short ratio (days): 3.94
Held by insiders: 0.33%
Held by institutions: 99.70%
Avg volume (3m): 1.84M
50-day average: 26.22
200-day average: 24.17
52-week change: −6.53%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 16.4
vs 50-day SMA: −28.10%
vs 200-day SMA: −22.28%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.23%
Realised vol (20d, ann.): 55.5%
From 52-week high: −39.44%
From 52-week low: +0.05%

ANR

Analyst Consensus

19 analysts

Consensus

Buy

1.80 on a 1 (strong buy) – 5 (sell) scale

Mean target

31.95

+70.39% implied

Low 17.00Median 33.00High 49.00

Recommendation trend

Now15 / 4 / 1
1m ago

DES

About ACADIA Pharmaceuticals Inc.

Yahoo Finance profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 796
Headquarters: San Diego, CA, United States
Website

SEAS

Seasonality · ACAD

2007–2026 · monthly returns

Strongest month Jul +6.71%Weakest month Oct −2.90%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.9	-2.3	-9.4	0.9	-3.5	16.8	2.3	11.8	-30.3	-6.9			−29.8%
2025	1.7	5.0	-15.3	-12.1	47.7	0.0	10.5	9.1	-17.9	6.4	10.3	6.7	+45.6%
2024	-17.2	-10.3	-20.4	-9.6	-9.6	7.6	17.0	-12.8	-7.2	-5.1	11.9	12.4	−41.4%
2023	19.5	8.7	-9.0	13.3	10.2	1.9	22.1	-7.6	-22.9	8.3	-1.3	40.5	+96.7%
2022	-3.6	13.0	-4.7	-23.9	-12.4	-12.8	4.3	11.8	-0.4	-2.0	-2.8	2.2	−31.8%
2021	-10.1	1.9	-47.3	-20.3	8.7	9.2	-11.3	-19.0	-5.1	8.1	7.0	21.6	−56.3%
2020	-6.6	7.0	-1.1	14.3	2.8	-2.4	-14.2	-4.8	4.2	12.6	22.0	-5.6	+25.0%
2019	40.9	16.3	1.3	-10.4	-0.2	11.4	-8.0	12.5	30.1	17.8	6.8	-5.5	+164.6%
2018	-0.7	-16.7	-9.8	-29.6	14.5	-15.6	-1.2	-5.8	46.0	-6.2	-2.2	-15.2	−46.3%
2017	19.9	10.2	-9.8	-0.1	-25.1	8.5	6.7	19.6	5.8	-7.5	-13.1	-0.5	+4.4%
2016	-42.0	-16.6	62.0	15.5	9.7	-8.4	14.1	-13.3	-1.0	-26.7	15.8	6.9	−19.1%
2015	-4.2	24.8	-14.2	4.8	20.6	1.7	16.5	-25.0	-9.7	5.3	9.0	-6.1	+12.3%
2014	-6.8	21.5	-14.0	-17.3	2.6	9.4	-10.3	18.3	3.3	11.9	7.8	6.3	+27.1%
2013	29.7	0.7	30.8	62.3	9.2	29.0	8.5	1.3	37.6	-17.3	2.5	7.3	+437.4%
2012	39.8	10.6	28.7	-30.2	-8.0	27.5	-8.5	10.6	42.1	-7.1	121.3	-10.6	+330.6%
2011	41.7	-11.2	7.3	69.8	-31.3	-13.8	0.0	-16.6	-20.6	13.9	-20.3	10.2	−10.0%
2010	-5.3	4.8	15.3	9.9	-19.3	-18.7	11.9	-17.2	-9.9	-16.5	-11.8	79.1	−9.1%
2009	12.2	-17.8	14.5	4.2	98.0	11.7	85.8	43.5	-70.7	-24.0	-5.4	7.3	+46.7%
2008	7.1	-16.4	-8.7	-11.7	10.0	-58.1	-19.2	-14.4	5.1	-29.1	-32.6	-29.7	−91.9%
2007	-18.7	-2.7	115.8	-9.1	-6.4	6.9	2.7	2.5	4.6	2.2	-26.3	-2.4	+25.9%

INSD

Insider Activity · ACAD

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

141.6K shares

Sells, 6 months

58.4K shares

Net shares

+83.3K

Net change in insider shares

+17.20%

Date	Insider	Transaction	Shares	Value
Aug 5, 2026	Schneyer Mark C.Chief Financial Officer	Sale at price 29.00 - 29.34 per share.	20.1K	$587.24K
Aug 5, 2026	Schneyer Mark C.Chief Financial Officer	Conversion of Exercise of derivative security at price 17.84 per share.	20.1K	$359.31K
Jul 29, 2026	Thompson Elizabeth H.Z.Officer	Sale at price 26.13 - 26.17 per share.	16.6K	$432.66K
Jul 28, 2026	Thompson Elizabeth H.Z.Officer	—	32.3K	—
Jun 25, 2026	Kihara JamesOfficer	Sale at price 26.08 per share.	11.4K	$297.91K
May 28, 2026	Daly James M.Director	—	8.1K	—
May 28, 2026	Poole JonathanDirector	—	2K	—
May 28, 2026	Garofalo Elizabeth Amy M.D.Director	—	8.1K	—
May 28, 2026	Ndu AdoraDirector	—	8.1K	—
May 28, 2026	Brege Laura ADirector	—	8.1K	—
May 28, 2026	Baker Bros Advisors L.P.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	37.2K	—
May 28, 2026	Harrigan Edmund P. M.D.Director	—	8.1K	—
May 25, 2026	Kihara JamesOfficer	Sale at price 21.18 per share.	5.4K	$114.39K
May 3, 2026	Kihara JamesOfficer	Sale at price 21.79 per share.	1.3K	$29.02K
May 3, 2026	Schneyer Mark C.Chief Financial Officer	Sale at price 21.79 per share.	3.5K	$76.40K
Apr 30, 2026	Kihara JamesOfficer	—	2.6K	—
Apr 30, 2026	Schneyer Mark C.Chief Financial Officer	—	6.8K	—
Apr 6, 2026	Kihara JamesOfficer	Sale at price 22.20 per share.	1K	$22.87K
Apr 6, 2026	Schneyer Mark C.Chief Financial Officer	Sale at price 22.20 per share.	2.7K	$60.14K
Apr 1, 2026	Kihara JamesOfficer	—	2K	—

13F

Investors Holding ACAD

latest 13F filings of 29 followed managers

Investors holding ACAD
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$32.4M	0.04%	1.28M	−26%	Q2 2026
Bridgewater Associates · Ray Dalio	$1.3M	0.01%	50.27K	−65%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ACAD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ACAD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ACADIA Pharmaceuticals Inc.

Seasonality · ACAD

Insider Activity · ACAD

Congress Trades · ACAD

Investors Holding ACAD

Investors Holding ACAD

Congress Trades · ACAD

Insider Activity · ACAD

Seasonality · ACAD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ACADIA Pharmaceuticals Inc.

Financial Snapshot

Earnings & Dividends

News